Sukanto Sinha, Ph.D., is a co-founder of ActiveSite, and its chief
executive officer. Dr. Sinha is an
inventor of the platform technology of the company. Prior to starting ActiveSite, Dr. Sinha held
multiple research and executive positions at Athena Neurosciences/Elan
Pharmaceuticals from 1988-2005, most recently as Vice President, Research. During this time, Dr. Sinha established and
led the new target discovery group at Elan, resulting in the discovery of BACE,
a key protease target for Alzheimer's Disease, in 1998. He subsequently led the largest small
molecule drug discovery project at Elan, BACE inhibitors for Alzheimer's
Disease, a joint venture with Pharmacia from 2000-2003. His wide experience in new target discovery
for neurodegenerative disease and preclinical drug discovery for new protease targets
is reflected in being a named inventor on thirty issued U.S. patents,
and an author on forty-two peer-reviewed publications and four book chapters.
Tamie
Chilcote, Ph.D., the other co-founder of ActiveSite, is its chief operating
officer, and a co-inventor of the platform technology which drives the company's
drug discovery engine. Following post-doctoral work in neuroscience at Rockefeller University
and Yale University, Dr. Chilcote joined Athena
Neurosciences/Elan Pharmaceuticals in 1994, where over the following 11 years she
identified protease and kinase targets involved in neurodegenerative diseases
and established novel assays for enzymatic, cell-based and protein-protein
interaction screening. Notably, Dr. Chilcote and her team established that
Ser-129 phosphorylation of α-synuclein by the protein kinase PLK-2 is a key
pathological process in Parkinson's Disease.
Dr. Chilcote is an inventor on eight issued U.S. patents, and an author on twenty-three peer-reviewed publications. She is also the principal investigator on SBIR
grants from the NIH awarded to ActiveSite.
|